We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
NIVO-ALCL - Phase II trial of nivolumab for paediatric and adult relapsing/refractory ALK+ anaplastic large cell lymphoma, for evaluation of response in patients with progressive disease (Cohort 1) or as consolidative immunotherapy in patients in complete remission after relapse (Cohort 2)
Towards inhibiting cut-and-run: An aberrant V(D)J recombination reaction that leads to lymphoid cancers
Understanding and improving the mechanism of action of anti-GD2 monoclonal antibody therapy in neuroblastoma
Improving prediction of relapse, treatment delivery and outcomes for children with renal tumours in the UK
The use of proton beam therapy to improve outcomes in childhood abdominal tumours
Investigation of potential therapeutic targets in paediatric aggressive B-cell non-Hodgkin lymphoma - towards kinder, more effective treatments
Repurposing of drugs targeting drug resistant self-renewing Ewing’s sarcoma cells to accelerate new treatments into clinical trials to improve outcomes.
Targeting mutant NRAS in paediatric AML
Targeting Myeloid-Derived Suppressor Cells (MDSCs) and Tumour-Associated Macrophages (TAMs) with the anti-CD33 immunotoxin Gemtuzumab ozogamicin to restore anti-cancer immunity
